Key facts
- Hemeris’s last known valuation is $8.6M (Oct 2025).
- It has raised $1.1M; the latest was Later Stage VC ($1.1M) in Oct 2025.
- Notable investors include Regenerative (Swiss), 21st by CentraleSupélec, ESSEC Alumni Business Angel.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Hemeris
- ·The full record, as it builds
Funding rounds
No funding rounds for Hemeris are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Hemeris
Operator of seed decontamination technology intended for removing bacterial and fungal pathogens from agricultural seeds. The company offers atmospheric cold plasma in a dry, residue-free process, applies controlled and species-specific treatments, operates at an industrial scale, relies on validated laboratory protocols, and is delivered as an in-house service, enabling seed producers and agricultural operators to reduce contamination, preserve germination rates, avoid chemical treatments, and meet sustainability and production requirements.
- Sector
- Materials and Resources
- HQ
- Gif-sur-Yvette, France
- Founded
- 2021
- Website
- hemeris.bio/
- Ownership
- Privately Held (backing)
Hemeris doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hemeris shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hemeris in its N-PORT filings yet. We sweep new filings monthly.